• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regentis Biomaterials Ltd. Ordinary Shares (NY:RGNT)

2.210 +0.060 (+2.79%)
Official Closing Price Updated: 8:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair
May 22, 2026
Via Investor Brand Network
News headline image
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
April 16, 2026
Via ACCESS Newswire
News headline image
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
March 17, 2026
Via ACCESS Newswire
News headline image
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
February 24, 2026
Via ACCESS Newswire
News headline image
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
February 19, 2026
Via ACCESS Newswire
News headline image
Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs
February 17, 2026
Via ACCESS Newswire
News headline image
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
February 04, 2026
Via ACCESS Newswire
News headline image
Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
January 20, 2026
Via ACCESS Newswire
News headline image
Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation
January 06, 2026
Via ACCESS Newswire
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Secures New U.S. Patent for GelrinC Liquid Formulation
January 05, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC
December 18, 2025
Via ACCESS Newswire
News headline image
Regentis Biomaterials Commences Trading on NYSE: Set to Transform Cartilage Repair Market with Off-the-Shelf Regenerative Product
December 08, 2025
Via ACCESS Newswire
News headline image
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
December 05, 2025
From Regentis Biomaterials Ltd.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap